Level and Value of Interleukin-18 in Patients with Acute Myocardial Infarction Undergoing Primary Coronary Angioplasty.
From: Cardiology Department, Suez Canal University Hospital, Ismailia, Egypt.
Circulation journal : official journal of the Japanese Circulation Society
- Publish Date: May 2007
- ISSN: 1346-9843
- Volume: 71
- Issue: 5
- Pages: 703-8
- Medium: Print
- Language: English
- Citation (JAMA): Youssef Ali A, Chang Li-Teh, Hang Chi-Ling, et al. Level and Value of Interleukin-18 in Patients with Acute Myocardial Infarction Undergoing Primary Coronary Angioplasty.. Circ. J. May 2007;71:703-8
Abstract
BACKGROUND: The prognostic value of interleukin (IL)-18 in patients with ST-segment elevation acute myocardial infarction (STEMI) is currently unclear. Thus, the purpose of this study was to test whether the circulating IL-18 level can predict prognosis in patients with STEMI undergoing primary percutaneous coronary intervention (PCI). METHODS AND RESULTS: A prospective cohort study was conducted with 267 consecutive patients with STEMI of onset <12 h who were undergoing primary PCI. Blood samples for plasma IL-18 level were collected in the catheterization laboratory following vascular puncture. The plasma IL-18 level was also evaluated in 25 healthy and 30 at-risk control subjects. The plasma level of IL-18 was significantly higher in acute myocardial infarction (AMI) patients than in both groups of control subjects (all p<0.0001). Patients with high plasma IL-18 level (> or =560 pg/ml) had significantly higher peak creatine kinase-MB levels, higher incidence of cardiogenic shock upon presentation, significantly lower left ventricular ejection fraction (LVEF), lower successful reperfusion and significantly higher incidence of 30-day composite major adverse clinical events (MACE) (advanced congestive heart failure > or = class 3 or 30-day mortality) than those patients with low plasma IL-18 level (<560 pg/ml) (all p<0.0001). Multiple stepwise logistic regression analysis demonstrated that high plasma IL-18 level (> or =560 pg/ml) along with low LVEF (<50%) and cardiogenic shock were the most independent predictors of 30-day MACE (p<0.0001). CONCLUSIONS: In patients with STEMI, plasma IL-18 level is a major independent inflammatory predictor of 30-day MACE. Evaluation of circulating IL-18 might improve the prediction of unfavorable clinical outcomes following AMI.
Mesh Headings (Keywords): Aged, Angioplasty, Transluminal, Percutaneous Coronary, Coronary Angiography, Electrocardiography, Female, Heart Failure, Humans, Interleukin-18, Male, Middle Aged, Myocardial Infarction, Prognosis, Risk Factors, Shock, Cardiogenic, Stroke Volume, Time Factors
Check for Full Text / PubMed Unique Identifier (PMID): 17456995
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.